Skip to main content

User menu

  • Sign in
  • Register

Main menu

  • Pfizer Medicines
  • Therapy Areas
  • News
  • Materials
  • Useful Links

Search form

Pfizer Home
  • IBRANCE® (palbociclib)

Clinical Information

  • Prescribing information for IBRANCE® (palbociclib)
  • Mechanism of action
  • Frequent adverse events
  • Dosing
  • Cardiovascular information
  • IBRANCE® palbociclib PALOMA-2 trial
  • PALOMA-3 Trial
  • Clinical and real world experience
  • Adapting breast cancer care during COVID-19 pandemic
  • Service Support Resources
  • Service Support Resources

Useful Resources

  • Video Resources (5)
  • Links and resources (1)

This site is intended only for healthcare professionals resident in the United Kingdom

IBRANCE is indicated for the treatment of HR+/HER2-, locally advanced or mBC in combination with an AI or with fulvestrant in women who have received prior ET. In pre-and peri-menopausal women, the ET should be combined with a LHRH agonist.

IBRANCE: Breast cancer simulation

Healthcare service redesign and transformation
Duration: 
04:16

The Ibrance Simulator is a Promotion resource, used by Pfizer Oncology Healthcare Development Managers, that will be used in Ibrance Promotional conversations.

Discrete event simulation is an effective form of scenario generation and engagement around service transformation for healthcare. It can be used to model hospital departments, pathways or entire health economies in an animated and compelling manner.

Simulations are communication tools. They open debate, they enable conversations and engender close working with hospitals and wider healthcare commissioning towards all round healthcare improvements.

The objective of the Ibrance simulation model is to demonstrate, to NHS stakeholders, the benefits of adopting Ibrance for the treatment of ER +ve, HER2 -ve patients with advanced breast cancer in the following key points:

  1. Firstly the freeing of capacity in the chemotherapy clinic and cost savings by adopting Ibrance to delay disease progression and chemotherapy treatment.
  2. Secondly, further Service optimisation by moving away from a consultant led or secondary care led service where appropriate.

The results from all scenarios can be exported into a results summary and, on request, the Results Summary Document and Data Analytics resource, can be provided to Healthcare Professions (HCPs) directly from the resource.

How could IBRANCE make a difference to your service capacity and Optimisation ?

Speaker

Pfizer Oncology

PP-IBR-GBR-2225. February 2020

Pfizer Home
  • IBRANCE® (palbociclib)

Clinical Information

  • Prescribing information for IBRANCE® (palbociclib)
  • Mechanism of action
  • Frequent adverse events
  • Dosing
  • Cardiovascular information
  • IBRANCE® palbociclib PALOMA-2 trial
  • PALOMA-3 Trial
  • Clinical and real world experience
  • Adapting breast cancer care during COVID-19 pandemic
  • Service Support Resources
  • Service Support Resources

Useful Resources

  • Video Resources (5)
  • Links and resources (1)

Janrain Capture

  • Register / Sign in

Footer menu

  • Report Adverse Events
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • Pfizer.co.uk

Copyright footer block

Copyright © 2016-2020 Pfizer Limited. All rights reserved.
This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration number GB201048427.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit
www.medicines.org.uk/emc.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
PP-PFE-GBR-2464. April 2020

For healthcare professionals only*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select ‘No’, you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer’s prescription medicines.

*The ABPI Code definition of healthcare professional is members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-GIP-GBR-3015 March 2018

YesNo
Your login attempt failed. Please try again.

{* message_withExistingAccount *}

{* loginWidget *}

{* message_joinNow *}

{* message_joinNowText *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* traditionalSignIn_createButton *}

{* message_signIn *}

Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* loginWidget *}
{* message_useAnotherAccount *}
Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* message_useAnotherAccount *}

{* message_registeringThankYou *}

{* message_confirmEmailSent *}

{* message_close *}

{* message_confirmTraditionalInformation *} {* message_alreadyHaveAccount *}

* Required Information

{* #registrationForm *} {* salutation *} {* givenName *} {* familyName *} {* email *}
{* designation_name *} {* designation_specialty *} {* designation_specialty2 *} {* designation_specialty_json *} {* primaryAddress_workplace *} {* primaryAddress_postalCode *} {* phoneNumber_work *} {* license_number *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} {* acknowledgement_professional *} {* acknowledgement_consent *} {* acknowledgement_terms *}
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."
{* hidden_programType *} {* hidden_campaign *} {* hidden_siteId *} {* hidden_preferredLanguage *} {* hidden_residencyCountry *}

PP-PFE-GBR-2768 September 2020
{* backButton *}
{* createAccountButton *}
{* /registrationForm *}
{*#postLoginAcceptanceForm*}

{* message_legalText *}

{* postLoginAcceptanceButton *}
{*/postLoginAcceptanceForm*}

{* message_emailPasswordResetInstructions *}

{* #forgotPasswordForm *} {* traditionalSignIn_emailAddress *}
{* backButton *}
{* forgotPassword_sendButton *}
{* /forgotPasswordForm *}

{* message_emailPasswordResetSent *}

{* message_close *}
{* mergeAccounts *}
{* #tradAuthenticateMergeForm *} {* traditionalSignIn_emailAddress *} {* mergePassword *}
{* backButton *}
{* traditionalSignIn_signInButton *}
{* /tradAuthenticateMergeForm *}